Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hayward strikes again !
He's been pushing this rope for years.
APDN is good to one shareholder: Jim Hayward.
Yet, the wide eyed awe of investor disappointment
continues.
A 40-1 RS was the only PR anyone should care about.
He's old, so when he folds his tent, It'll require
a monstrous hustle to sell tickets to "step right up"
and see the disappearing company.
Thanks,
I'm trading on Canon's DD in taking a stake in TTOO, plus other
recent company developments.
Appreciate your informative reply!
Enjoy!
2 questions: what is the name of the competitor ?
And,does Canon know what you know ?
That Israel would endorse Applied DNA technology is testimony
to the efficacy of the science.
That Israel is the first to do so, underlines the rigor to which they are willing to subject any aspect of their National security.
The use of tagging adds a mechanical complication to production
that, I think, highlights the paranoia of being the bullseye of muslim hatred.
A purely defensive move by a country where security is as vital as oxygen.
Why is ADNAS failing you ask ?
Blockchain!
Why bother with a high maintenance contraption spewing gunk
all over everything, when any kluts with a cellphone and thumbs
can track anything, anywhere, at anytime.
There may be some salvage value in their medical DNA IP,
but nothing else.
The pocket change of the latest finance folly may relate
to that hope.
Manufacturers see adding dna tracing as complicated,
unwieldy, and evermore, as redundant to other tracking tech.
With blockchain, even in barcode ink, it is being obsoleted.
Linearx is a cry for help. Yet it is their only hope.
No credible pharma company shows interest, yet at Investor day
the only analyst (Maxim) wanted to know where they would
locate their “off the shelf” cancer cure dispensers.
It is a long and complex path to FDA approval, requiring many
millions of dollars, and years of research, usually associated
with companies that have the resources to fund and coordinate
the efforts.
I think that if their medical dna was as revolutionary as claimed,
they would have successfully shopped it by now.
Instead, they are reduced to employee funding, and last gasping
about their final rainbow.
Hi, I’ve moved on.
I’m no longer interested in supply chains. I’m going to get rich
curing Cancer.
The Computer is the ultimate medical technology. It’s ability to
sort and select data at ever faster rates from a body of medical
knowledge that is doubling every 75 days is transforming Biotech.
Adnas DNA may have value as a test bed for research, but it is
up against enormous companies with huge financial resources.
Their real, and perhaps only, hope is to garner interest from an
established player that can integrate Adnas’ IP into research of their own.
They need money, and they don’t have it. Without it they can’t be relevant for long.
If they drop a big name or two today, things could improve
You are already invested in one.
TraceLink is funded by 1. Georgian Partners, Willett Advisors LLC, Vulcan Capital, Goldman Sachs, FirstMark Capital, Volition Capital and F-Prime Capital.
2. ADNAS IS FUNDED BY ?
Thanks for an informative and interesting hour.
I know very little about anything, but my ignorance of Biology was no barrier to slipstreaming Genentec in buying a small amount of Affimed.
Betting on their analysis, I figured $5 billion a reasonable valuation.
Juno Therapeutics had similar issues, but was ultimately acquired by Celgene for $9 billion.
They settled for $24 million in a class action for not immediately disclosing 3 deaths in a trial.
Legalizing Weed will transform the POT market.
Enter big pharma: Exit local growers.
Think Tobacco.
If the government regulates it, production will be standardized. Huge acreage devoted to mass production will be more easily controlled.
Meanwhile, research into the molecule, hitherto limited by the legality, and scarcity issues, will expand.
Who knows where that will lead ?
The local grower could exist on the margin, but, challenged by the complexity of government regulation, limited to secondary markets.
Consuming THC in a beverage or edible is much more convenient and less disruptive than firing one up.
I wouldn’t mind socializing with a six pack of “Pot Lite”.
Visions of ADNAS plugging their chemistry into a production process, other than in ink, are probably wrong.
The IP of PCR DNA production evidently has merit, and, customers.
I think the value of the company lies there. The rest is baggage.
Years of rainbow chasing with ADNAS has cultivated a cynical view.
All the potential “Verticals” touted by management thru the years have not produced enough revenue to pay the bills.
I think “dna tagging” is being obsoleted by a combination of technologies, among them, spectroscopy and blockchain.
The new subsidiary may just be a way of allowing the existing (lack of) business to fade away while Linearx makes shareholders rich vaccinating the World against Cancer.
The fact that the $1.65 million pp was less than half the amount offered, is another disappointment.
Adnas has been stumbling along for years. Maybe the tech is just too cumbersome, and might be obsolete.
Spectrometry is an alternative. Moving the process out of lab into the field has hurdles tho.
One start up, LinkSquare has a handheld reader they are developing.
Imagine just testing Cotton’s and Viagra’s spectral fingerprint as opposed to Adnas’ method.
Harerabbit’s post did it for me.
The “Miracle PR” !
Been waiting for it for years. My deer in the headlights investing habits have cost me lots.
When the company pulls it’s guidance, and an analyst on the call is not challenged when he
tells the CEO and CFO that the numbers “don’t add up”, I could hear the fat lady tuning up.
There may well be a Miracle PR, but, were I tempted to buy back @ $10.00, there would surely
be proven value in the product.
The corrosive and puny financing schemes the company resorts to reflect Wall Street’s
opinion.
Good luck to all, but I’m out.
46,000 @ $1.11 bid.
A not so eager buyer, or patient short ???
The shorts are in charge now.
Barring some wondrous intercession by an entity that has mutual interests with ADNAS,
the shorts will be able to bid low, wait, and buy back. With each profitable short, they
borrow more and bid lower. Ultimately, huge blocks sit on an ever lower bid like a cancer.
No time limit.
When all is said and done, they scavenge the IP for pennies.
Sabby come to mind ?
The shorts are in charge now.
Barring some wondrous intercession by an entity that has mutual interests with ADNAS, the shorts will be able to bid low, wait, and buy back.
With each profitable short, they borrow more, and bid lower. Ultimately, huge blocks sit on an ever lower bid like a cancer.
No time limit.
When all is said and done, they scavenge the IP for pennies.
Sabby come to mind ?
Your numbers don’t add up!
So said one analyst on the call.
Foose is right. Doctor H. is constantly misdirecting investors
to the next Rainbow chase. He can’t hustle pocket change from
any worthwhile source, so, a shark like Sabby feasts on what is rapidly becoming a carcass.
Note also, his emphasis on the value of the IP.
Oh ! Don’t forget ! If one state legislature adopts Theracann!
Pulling guidance destroys any credibility he had.
The cotton Pr was dishonest. He knew the payment terms when he shipped it, yet he allowed the perception of Q3 revenue to persist.
Enough is enough.
Predicted loss of 3 cents this Q.
Last Q a 12 cent loss was expected. They beat by a nickel,
losing only $.o7.
If they beat by only 3 cents Monday, it is break even.
A milestone !
I am not predicting a 5 cent profit, but would be very pleased
if that happened.
Usually after close on Thursday.
Etrade expects (.03)
Last quarter, a loss of .12 was expected, they beat by .05
for .07 loss.
A 5 cent surprise = profit.
Another handicapper for small stocks:
Before bell Monday = strong buy !
Calls made after close on Friday = strong sell !
Wouldn't surprise me to hear mention of imminent profitability !
The earnings release timing bodes well !
Been criticized for rating day and time numerically, but I think Monday, after market close rates a “9" out of a possible “10" .
On a 1 thru 10 scale, before the bell Monday = a “10" .
The value decreases sequentially by day and time, with after the bell on Friday earning a “1".
Scientifically baseless, but psychologically significant.
About to commemorate my 300th or so anniversary. I got shackled before Hydrogen met Oxygen. Probably saved me from death in my early thirties.
I’m a shiftless mutt, self indulgently destructive by nature.
I envy my dog.
No foresight, no hindsight, completely absorbed in “now”. Chasing things and eating, are his priorities.
Lust tricked me into a life of responsibility. Not quite weasel enough to renege on promises made in a borrowed suit before witnesses, I was forced into decades of a structured, responsible role as husband, parent, and breadwinner.
Retired now, my wife and I are good friends and partners.
She and the feminine desire for society reined my behavior to moderation and punctuality, saving my life in the process.
Overall, a beneficial experience.
Worth the effort.
The need for a special “reader” to identify dna tags will always be a huge
barrier. Got to have a barcode type scanner with a software key that
can be accessed on any loading dock to really be main stream.
I think the UL pr hints at the possibility.
Thanks,
Happy 4th!
I hope the unnatural silence is do to negotiations that might
be affected by change in share price
Cotton gins produce their product for less than a dollar per pound.
Adding a penny or two a pound to costs by squeezing dna tagging
into the process is obviously (7 U.S. gins) not an easy process.
Pot leaves the "grow" at over $2000.00 a pound.
I never really cared about the length of fibers in my sheets or
"T" shirts.
Very interested in the pedigree of pot products I might choose to consume, however.
Consumer protection achieves a necessary elevation when attempting
to homogenize the production of pot
An excerpt from a February 5, 2018 Theracann PR:
This is an exciting time for this industry," Dr. Weinthal says "the ability to partner with a leading technology firm like TheraCann allows this science to innovate faster to deliver new products and solutions to protect legal cannabis markets worldwide."
The global legal cannabis economy is expected to reach $140 Billion within 10 years with many Countries expanding medical and recreational usage restrictions in 2018. Australia , Canada , the United States , Columbia and Uruguay have already seen dramatic growth in their cannabis sectors, however the prospect of illegal products entering the legal supply chain remains a serious concern in each case. A new report by Arcview Market Researchi asserts that even though legal North American cannabis sales rose to $6.9 Billion in 2016, 87% of all cannabis sales still come from black or grey market sources.
Chris Bolton , Chief Operating Officer of TheraCann International, says "The future of the cannabis marketplace is in transforming the black-market system to legal and regulated sources. True traceability including the ability to track products from cultivation, extraction and derivative processing in to edibles or other forms, will provide a clear method to eliminate black market products from entering the regulated marketplace."
This latest patent agreement fits with TheraCann's recent joint venture announcement with TKS Ventures (dba Tokes Platform)ii and multi-year agreement with Applied DNA Sciences Inc (APDN)iii to provide an immutable link between the authenticity of goods and the authenticity of digital transactions to create a unique and forensic identifier throughout the cannabis supply chain.
"Beyond the obvious cost savings in enforcement and diversion control," says Bolton, "The consumer should be protected from harmful or even dangerous products entering the market, the retailer should be protected in the event of recall or product deficiencies, and the government or regulatory body should have the confidence to know, with certainty, that a product produced from a licensed facility is the same product that is ultimately sold to consumers."
Applied DNA Sciences, Inc. is engaged in creating security solutions addressing the challenges of modern commerce. The Company is also engaged in the large-scale production of specific deoxyribonucleic acid (DNA) sequences using the polymerase chain reaction (PCR). Its principal technology platform includes SigNature DNA, SigNature T DNA, fiberTyping, DNAnet, digitalDNA, SigNify and Beacon.
Its SigNify IF portable DNA reader provides definitive real-time authentication of SigNature DNA
DNA for 31 million pounds of cotton in Australia.
Harleysville, Penn. and Horgen, Switzerland: Friday, September 23, 2016 - November 06, 2016 -
Colorcon Inc. and The Dow Chemical Company (NYSE: DOW
announced today an agreement to broaden the existing Controlled Release Alliance between the two companies. While the Alliance currently provide controlled release technologies from
Dow Pharma & Food Solutions, a business unit of Dow,
to customers, effective January 1, 2017, it will be extended to include Dow's advanced technology based pharmaceutical excipients.
A search under Consumer Care on the Dow page yields this 2016 release:
Dow and Colorcon Extend and Broaden the Scope of the Controlled Release Alliance:
Harleysville, Penn. and Horgen, Switzerland: Friday, September 23, 2016 - November 06, 2016 - Colorcon Inc. and The Dow Chemical Company (NYSE: DOW) announced today an agreement to broaden the existing Controlled Release Alliance between the two companies. While the Alliance currently provide controlled release technologies from Dow Pharma & Food Solutions, a business unit of Dow, to customers, effective January 1, 2017, it will be extended to include Dow's advanced technology based pharmaceutical excipients.
About Dow Pharma & Food Solutions
Dow Pharma & Food Solutions designs differentiated solutions that enable pharmaceutical delivery & nutritional benefits to customers around the world. A business of Dow Consumer Care portfolio, Dow Pharma & Food Solutions offers a single interface to all Dow technologies and expertise focused on solutions serving the pharmaceutical and food manufacturing markets. We provide functional excipients, active pharmaceutical ingredients (APIs) and highly functional food ingredients to help consumers live healthier, more convenient and enjoyable lives. Dow Pharma & Food Solutions employs 1,200 people across nine sites and 15 manufacturing plants, with six cGMP's, serving customers in around 160 countries. Additional details can be found at www.dowpharmaandfood.com.
About Dow
Dow (NYSE: DOW) combines the power of science and technology to passionately innovate what is essential to human progress. The Company is driving innovations that extract value from material, polymer, chemical and biological science to help address many of the world's most challenging problems such as the need for clean water, clean energy generation and conservation, and increasing agricultural productivity. Dow's integrated, market-driven, industry-leading portfolio of specialty chemical, advanced materials, agrosciences and plastics businesses delivers a broad range of technology-based products and solutions to customers in approximately 180 countries and in high-growth sectors such as packaging, electronics, water, coatings and agriculture. In 2015, Dow had annual sales of nearly $49 billion and employed approximately 49,500 people worldwide. The Company's more than 6,000 product families are manufactured at 179 sites in 35 countries across the globe. On June 1, 2016, Dow became the 100 percent owner of Dow Corning Corporation’s silicones business, a global company with sales of greater than $4.5 billion in 2015, 25 manufacturing sites in 9 countries and approximately 10,000 employees worldwide. References to "Dow" or the "Company" mean The Dow Chemical Company and its consolidated subsidiaries unless otherwise expressly noted. More information about Dow can be found at www.dow.com.
About Colorcon
Colorcon is a world leader in the development, supply and technical support of specialty excipients: formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Our best-in-class products and technologies are complemented by our extensive application data and value-added services to support all phases of solid oral dose design, development and manufacture. Our focus on market issues and technology development has earned Colorcon an international reputation as a pharmaceutical supplier of choice. That reputation is based on superior product quality, unparalleled technical support, extensive regulatory assistance and reliable supply from multiple locations. Colorcon currently has 10 manufacturing facilities (including six film coating sites), 19 technical service laboratories globally and more than 1200 employees exclusively dedicated to its customer base. For more information, visit www.colorcon.com.
Reassuring, that in a comprehensive evaluation by the world’s largest manufacturer of Solid On Dose coatings, ADNAS was chosen over TruTag.
While the exclusivity aspect of the agreement was a feature Dr. Hayward said he rejected in talks with another pharma company, he evidently thought differently this time.
An endorsement by the World’s largest, at “anything”, is an imprimatur.
"BUD" Beer.
Alcohol free, marijuana infused beer to be on market this Fall.
Reeks of potential to monitor ingredients.
All the buzz without the hangover.
What a market to capture.
An attempt to estimate the potential of the contract can be made
by using info on Rosier's site.
One boatload could be as much as 12 million pounds.
"Rosier’s products are mainly supplied to agricultural co-operatives and the fertiliser trade. The majority of these fertilisers are supplied in bulk, but Rosier can also supply fertilisers bagged, a service provided, if the client so wishes, by our own packaging department.
Rosier is not just active in Western Europe. The qualities of our compound fertilisers are also appreciated in other parts of the world. Rosier’s strategic position on the Terneuzen-Gent canal provides access to the major European and global markets.
The Terneuzen-Gent canal is navigable for 65,000 tonne ships. At Rosier’s wharf, bulk ships can be loaded with cargo weighing up to 6,000 tonnes. For larger quantities, Rosier turns to the nearby ports of Terneuzen, Gent and Antwerp.
To transport its products, Rosier uses inward-bound ships, coasters and container ships (mainly via Antwerp). Transport by road and rail is also possible. Sas van Gent is right by the Antwerp-Gent-Lille-Paris motorway."
Rekoop ?
Sounds like something to do with a chicken.
On GHCL’s site the two o’s in the logo are actually pet bottles.
How the designers concluded the name would attract buyers of
bed goods eludes me.
Incorporating the “PET” acronym in the brand name would
make more sense.
Thanks, "association" is a better word.
I too, found other releases, none of which said merger.
The word “merger” was used twice in the article. It has a precise definition.
If ADNAS stock rose yesterday because the term was used incorrectly, people will lose money when the error is corrected.
se·man·tics
NOUN
1. the branch of linguistics and logic concerned with meaning.
the meaning of a word, phrase, sentence, or text:
merg·er
NOUN
1. a combination of two things, especially companies, into one:
"a merger between two supermarket chains" ·
Selbyn Noronha , CEO of ACG Capsules, commented on the “merger” between ACG and Applied DNA:
The “merger” will give pharmaceutical companies better tools to prevent counterfeiting through improved tracking solutions across the supply chain.
Difficult to speculate, no matter how conservatively, on possible revenue from any of their new lines. Odd, that the typical contract, when revenue is mentioned at all, often benchmarks at no more than $500 K a year.
The pie is still in the sky, more or less.
Todays’ PR says Dr. Hayward will be pandering to the bored witless at the wrong end of a long day on March 13th. Maybe he’s presenting in the lounge.
I do think something will eventually work. After all, everything they are doing is new.
That no source of any stature is willing put up the tiniest of sums to perpetuate the technology, says much.
My hope is that they beat with less of a loss than expected this year.
The one analyst covering them thinks $5.00 a share is possible. That is over 200% above todays’ price.
ACG Worldwide is the second largest manufacturer of empty hard capsules in the world.
ACG Worldwide has been serving the pharmaceutical industry for five decades and is the second largest manufacturer of empty hard capsules in the world. The group comprises of 13 companies, including subsidiaries in China, USA, Indonesia, Brazil and Europe.
ACG Worldwide has a presence in over 100 countries with its products and services, employing approximately 3,200 members that strive to provide world-class technology across multiple domains. We offer a complete range of solutions beginning with empty capsules; granulation and coating; capsule filling; tabletting; packaging films; blister packing and carton packing to the end-of-line solutions. With over 20,000 machine installations worldwide, it speaks lengths of the high quality standards we follow at ACG as well as complying with major international quality certifications or legislations.
ACG Worldwide is committed to a core corporate competence. Our research teams strive to develop innovative technology in order to continually give our customers the benefit of a cost competitive edge plus world-class technology. 'SciTech Centre', the group's 50,000 sq. ft. R & D center located in the heart of Mumbai, is a government-recognized research institution. Especially in the last 25 years, it has witnessed breakthroughs in dosage form development-including controlled-release-pharmaceutical engineering, veterinary and agricultural research, emphasizing on delivery systems.